Exosomes were used for hair loss treatment, showing results 33 days after the second session. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
A 22-year-old male experienced hair regrowth and improved hair health after using Minoxidil, Finasteride, and microneedling for nine months, with initial shedding but no significant side effects. Users discussed similar experiences with hair styling difficulties and shared tips for managing hair texture and side effects.
User shared progress pictures after 7 months of using 0.25mg finasteride daily and 1ml minoxidil twice daily, reporting no side effects and being thrilled with the results. Other users discussed the effectiveness of lower doses and the psychological impact of potential side effects.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
CB-03-01, also known as Breezula, is being considered as an alternative to DHT blockers for hair loss. Users are discussing its effectiveness, potential regrowth, side effects like scalp irritation, and hormonal impacts.
The conversation discusses the potential effectiveness of a Sult1a1 enzyme booster in enhancing the results of minoxidil for hair loss. Users express interest in the booster, hoping it will improve the effectiveness of oral minoxidil, especially for those who struggle with topical application.
Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.
The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.
The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.
The user experienced significant hair regrowth using 1mg finasteride every other day and 1ml topical minoxidil daily, with initial shedding but improvement by three months. Microneedling was also used, with adjustments to frequency and needle length for better results.
Hair loss discussion mentions using estrogen mixed with growth stimulants like oral minoxidil for scalp hair growth. Idea proposed for an artificial SARM-estrogen that only affects hair without body side effects.
A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.
The user reports positive results using a multi-peptide serum for hair density, combined with finasteride and melatonin, after stopping minoxidil. They experienced hair regrowth after previously losing hair despite using finasteride and minoxidil.
The user reported tiny hair growth in thinning areas and improved thickness after 56 days of using 1 mg oral finasteride, 2.5 mg oral minoxidil, and a serum with Redensyl, Anagain, Capixyl, and Procapil. They also take supplements and maintain a healthy lifestyle with no noticeable side effects.
Using minoxidil and finasteride to address hair loss, with questions about side effects and the possibility of microneedling for increased effectiveness.
Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
The user is discussing their hair loss treatment stack, which includes CB-03-01, Fluridil, Alfatradiol, Cosmerna, microneedling, and Stemoxydine. They have seen some new hair growth but wish they could use finasteride.
Finasteride may affect male offspring's fertility and hormonal balance, with debates on whether to discontinue use before conception. Some users report no issues, while others highlight the high doses used in rat studies.
The user felt pressured during a hair transplant consultation at Bosley, where they were advised to undergo FUT surgery and use a laser cap for maintenance, but did not meet with a doctor. Other users recommended seeking a second opinion from reputable doctors like Dr. Rassman and suggested trying finasteride first.
A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.